Midwest Trust 13F: Adds $5.9M to Eli Lilly and (LLY) Stake
Key Points
- Midwest Trust raised its stake in Eli Lilly and Company by 7.4%, acquiring 5,069 more shares to bring its total holding to 73,312 shares valued at about $84.8 million in an SEC filing on October 22, 2026.
- Eli Lilly and Company recently traded near $1,306.74, sitting well above its 50-day and 200-day moving averages as it approaches its next earnings report on October 29, 2026.
- Wall Street research firms maintain positive views on the stock, with recent target updates from JP Morgan, Morgan Stanley, Cantor Fitzgerald, RBC Capital, and Leerink Partners.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
Midwest Trust expanded its investment in Eli Lilly and Company LLY, lifting its holdings by 7.4% during the third quarter. According to a Form 13F filing filed with the SEC on October 22, 2026, the firm picked up an additional 5,069 shares. That brought its total ownership to 73,312 shares, with a reported value of $84,827,891 at the time of the filing. Eli Lilly closed at $1,306.69 on the day of the filing.
LLY
Eli Lilly and Company
What Changed in Midwest Trust's Eli Lilly and Company Position
Prior to this update, Midwest Trust owned 68,243 shares of the drug maker. The addition of 5,069 shares marked a 7.4% increase in the fund's position. The firm's total investment is worth over $84.8 million based on the end-of-quarter valuation.
Other Institutional Activity in Eli Lilly and Company
Other institutional investors also adjusted their positions in the pharmaceutical giant. Symphony Financial grew its holdings by 1,205 shares, ending with 7,802 shares worth about $9,191,438. Strategic Blueprint lowered its stake by 785 shares, leaving it with 12,911 shares valued at roughly $14,938,745. True North Advisors grew its position by 1,108 shares, bringing its total to 4,217 shares worth about $4,879,120. Lilly Endowment, Inc trimmed its holdings by 307,272 shares to hold 90,066,978 shares valued at about $117,689,614,205. PNC Financial Services Group, Inc. reduced its stake by 5,133 shares, ending with 51,322,720 shares worth roughly $67,062,881,989.
Eli Lilly and Company Stock Up 1.8%
Eli Lilly shares recently traded around $1,306.74, remaining right around the level seen when the filing was made. The stock sits roughly 10.4% above its 50-day moving average and about 20.7% above its 200-day moving average. Shares trade near the company's 52-week high of $1,311.75, well up from the 52-week low of $806.02.
Recent Earnings
Eli Lilly generated $79,660,039,680 in trailing twelve month revenue alongside earnings of $29.79 per share. The company operates with a net profit margin of 33.5% and posts a return on equity of 102.3%. The next corporate earnings update is scheduled for October 29, 2026.
Dividend
Eli Lilly pays an annual dividend rate of $6.92 per share, which translates to a dividend yield of 0.54%. The company distributes 21.7% of its earnings as dividends to shareholders.
Insider Buying and Selling at Eli Lilly and Company
Company insiders executed several sales prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total of $5,950,000. Officer Donald A Zakrowski sold 2,000 shares on August 10, 2026, at $1,185.01 per share, totaling $2,370,020. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share for a total value of $7,638,150.
Analysts Set New Price Targets
Wall Street firms frequently update their outlooks on Eli Lilly. On September 28, 2026, JP Morgan maintained an Overweight rating while lifting its price target to $1500.00 from $1400.00. Morgan Stanley kept an Overweight rating on October 7, 2026, moving its target to $1430.00 from $1419.00. Cantor Fitzgerald kept an Overweight rating on October 8, 2026, raising its target to $1440.00 from $1410.00. RBC Capital reiterated an Outperform rating on October 12, 2026, with a $1500.00 target. Leerink Partners maintained an Outperform rating on October 21, 2026, pushing its target to $1316.00 from $1309.00. Overall, the stock holds a consensus buy rating from 30 analysts, with a mean price target of $1,331.55.
About Eli Lilly and Company
Based in Indianapolis, Indiana, Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products worldwide. The healthcare company focuses on therapeutic areas like diabetes, oncology, and immunology, supporting its large market valuation.
Bottom Line
Investors are keeping an eye on the upcoming earnings report on October 29, 2026, to gauge the company's growth trajectory. Monitoring ongoing institutional filings and analyst revisions will provide further clarity on market sentiment.
Related Filing Alerts
Source: Midwest Trust's 13F filing on $LLY (Oct 22, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts